

# Panagiotis Panagiotidis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3403607/publications.pdf>

Version: 2024-02-01

21  
papers

569  
citations

1040056

9  
h-index

752698

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

979  
citing authors

#	ARTICLE	IF	CITATIONS
1	Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome. <i>Leukemia</i> , 2021, 35, 1745-1750.	7.2	15
2	Chronic myelogenous leukemia occurring in two brothers: The opposite sides of the same coin?. <i>Leukemia Research Reports</i> , 2021, 16, 100261.	0.4	1
3	A Study of Ribonucleotide Reductase mRNA Expression and Its Prognostic Role in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 4678-4678.	1.4	0
4	Paternal age and specific neurological soft signs as reliable and valid neurobiological markers for the diagnosis of patients with schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, , 1.	3.2	3
5	Changes in Alcohol Use Habits in the General Population, during the COVID-19 Lockdown in Greece. <i>Alcohol and Alcoholism</i> , 2020, 55, 702-704.	1.6	38
6	Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. <i>Haematologica</i> , 2020, 105, 2440-2447.	3.5	31
7	A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. <i>British Journal of Haematology</i> , 2020, 190, 736-740.	2.5	9
8	One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020, 18, 434-444.	2.0	4
9	The effect of baseline antipsychotic status on the 12-month outcome in initially stabilized patients with schizophrenia. <i>Human Psychopharmacology</i> , 2019, 34, e2712.	1.5	2
10	12-Month stability of neurological soft signs in stabilized patients with schizophrenia. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 451-461.	1.3	5
11	A case-control study of paternal and maternal age as risk factors in mood disorders. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 90-98.	2.4	8
12	Neurological soft signs in familial and sporadic schizophrenia. <i>Psychiatry Research</i> , 2019, 272, 222-229.	3.3	8
13	Prevalence and correlates of neurological soft signs in healthy controls without family history of any mental disorder: A neurodevelopmental variation rather than a specific risk factor?. <i>International Journal of Developmental Neuroscience</i> , 2018, 68, 59-65.	1.6	12
14	Paternal and maternal age as risk factors for schizophrenia: a case-control study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2018, 22, 170-176.	2.4	24
15	Neurological soft signs significantly differentiate schizophrenia patients from healthy controls. <i>Acta Neuropsychiatrica</i> , 2018, 30, 97-105.	2.1	17
16	Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2018, 103, 69-79.	3.5	35
17	Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. <i>Lancet</i> , 2015, 385, 1873-1883.	13.7	296
18	CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry. <i>Blood</i> , 2013, 122, 2735-2735.	1.4	1

#	ARTICLE	IF	CITATIONS
19	NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911). Blood, 2013, 122, 527-527.	1.4	9
20	Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). Blood, 2013, 122, 528-528.	1.4	49
21	Advances in the treatment of geriatric depression. Aging Health, 2007, 3, 495-507.	0.3	2